|Date||Analyst Firm||Analyst Name||Action||Rating||Action Price||Prior Price||Target|
You can purchase shares of Aerovate Therapeutics (NASDAQ: AVTE) through any online brokerage.
There are no as such competitors for Aerovate Therapeutics.
The latest price target for Aerovate Therapeutics (NASDAQ: AVTE) was reported by Evercore ISI Group on July 26, 2021. The analyst firm set a price target for 30.00 expecting AVTE to rise to within 12 months (a possible 115.67% upside). 4 analyst firms have reported ratings in the last year.
The stock price for Aerovate Therapeutics (NASDAQ: AVTE) is $13.91 last updated Mon Oct 25 2021 20:00:02 GMT+0000 (Coordinated Universal Time).
There are no upcoming dividends for Aerovate Therapeutics.
Aerovate Therapeutics’s $Q3 earnings are confirmed for after-market on $November 16, 2021.
There is no upcoming split for Aerovate Therapeutics.
Aerovate Therapeutics is in the Consumer Discretionary sector and Multiline Retail industry. They are listed on the NASDAQ.